NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...
U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...
Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more precise, tailored therapy plan. In the rapidly evolving landscape of oncology, ...
Consistently, first-line trials of immune checkpoint inhibitors in combination with chemotherapy have demonstrated overall survival benefit for patients with metastatic gastroesophageal cancer.
Agilent has received FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with esophageal or gastroesophageal junction carcinoma eligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results